Example of facebook iframe app using graph-API calls through php-sdk
Important notice! This post is probably outdated and my examples don't work due lack of "https".
This works now with PHP SDK (v.3.0.0) and up. I have changed this post after initial publish.
This is simple example of facebook iframe application which is not using FBML and it has link to authorise and gain access to "publish_stream" permission. It demonstrates how to use new php-sdk library and graph API for that. I was pretty much puzzled at first, because there was many ways and apis to achieve this.
Documentation and examples are confusing at moment to get started with apps. Especially when it comes to iframe app which has to ask permissions to access user data. Confusion is even greater because there is old way and the new way to do it. I wasted many hours to figure things out and get this basic sample working. Therefor I share this example and hope it saves hours for them who are also lost in documentation and examples.
Check it out
This app is published in facebook at moment. Feel free to check it out before trying it. Or download the source code right away. It is also aivable at github.
Some screenshots
If user has not logged in or not given any permissions for app, it will show
following contents. You could do automatic redirection, but I find this kind of approach much more user friendly
because it can see (if presented) upfront what value this app promises.
After clicking allow link, it will direct user to permission request dialog.
Notice the target parameter in that link. If it is not set "_top" it will show one extra (blank) FB page which is confusing.
After allowing this app, it will redirect back to previous page and this time we can do some interesting stuff.
Like posting post on user's wall and accessing friends list. Of course there is much more you can do.
Set it up
So you want to try this out and start developing your own cool facebook application based on this. Here is quick step-by-step walk trough.
2. Unzip contents into your web server. e.g: http://www.example.eu/fb-app-test/ where index would be accessed eg: http://www.example.eu/fb-app-test/index.php
3. Download latest 'facebook.php' (php-sdk) from github and place it next to index.php and config.php
4. Go to Facebook developers app - allow access if needed
5. Find the "Create new app" button on the top and click it
6. Fill in essential information form and click "Continue" button.
7. After creating app you should be in editing view. Find submenu canvas settings in "On facebook" menu on the right side
8. Set Canvas Page to whatever you like. It will be your application's URL at facebook
9. Set Canvas URL. This must point to URL where you unpacked package at second step, without the index.php. e.g: http://www.example.eu/fb-app-test/
10. Set Canvas type to Iframe
11. Fill in config.php which variables should be pretty much self explanatory. Values can be found here after clicking on your app.
12. Save and you should be done. Go have a test-drive by entering newly created FB canvas url into browser.
UPDATES
There has been some changes in facebook after writing this post. My example didn't work (2011 april) but when I enabled "OAuth 2.0 for Canvas" in advenced tab, it started to work again. 2011 july edited my app to work with latest PHP SDK (v.3.0.0) (and up)
Categories:
Facebook
- Programming
It is called iframe app because it runs inside facebook page trough iframe.
Its not working, Its not getting session becasue when i click on "Allow this app to interact with my profile" nothing happen it shows again this message instead of form. and i dont see any allow fb login box
url is http://apps.facebook.com/hassanfawad/
I got this error in facebook.php file:
Fatal error: Uncaught exception 'Exception' with message 'Facebook needs the JSON PHP extension.' in /var/www/vhosts/traffup.net/httpdocs/facebook/app/facebook.php:23 Stack trace: #0 /var/www/vhosts/traffup.net/httpdocs/facebook/app/index.php(8): require() #1 {main} thrown in /var/www/vhosts/traffup.net/httpdocs/facebook/app/facebook.php on line 23
Your servers PHP installation needs JSON extensions in order to get Facebook PHP-SDK to work. It's not SDK issue.
have a great day!
bye
$user = $facebook->getUser();
if ($user) {
try {
// Proceed knowing you have a logged in user who's authenticated.
$user_profile = $facebook->api('/me');
} catch (FacebookApiException $e) {
error_log($e);
$user = null;
}
}
"an error occurred, try later"
After the user clicks "Allow" the web browser is redirected to http://my-site/my-fb-site and not to http://apps.facebook.com/my-fb-site
What can I do? I'm using your latest version.
Made minor correction. Should be fine now.
Now the redirection is fine but when the web browser is redirected to http://apps.facebook.com/my-fb-site the "$user" variable is zero.
$user = $facebook->getUser();
echo $user;
// 0
$user = 0
I can't seem to get your code to work...
I keep being redirected to the page with the 2 links and the text. No code in the URL either..
I guess i'm making the same mistake as Hassan, a little further up, but his question was never answered... :(
-Mo
Have you tried using FBML tags? I want to use tags like fb:friend-selector, fb:name, fb:dialog etc...
Thanks. But I have not used FBML tags somewhere yet.
1. Paste this code just after your <body> tag:
<div id="fb-root"></div>
<script type="text/javascript" src="http://connect.facebook.net/en_US/all.js"></script>
<script type="text/javascript">
FB.init({
appId : '<?php echo $fb_app_id; ?>',
status : true, // check login status
cookie : true, // enable cookies to allow the server to access the session
xfbml : true // parse XFBML
});
</script>
2. Wrap your fbml tag inside a fb:serverfbml block as follows (using friend-selector as an example):
<fb:serverFbml style="width:195px;height:17px;">
<script type="text/fbml">
<fb:fbml>
Choose a Friend: <fb:friend-selector />
</fb:fbml>
</script>
</fb:serverFbml>
That's it. You will see the ajax loading animation and the fbml tag will render in a few seconds :-)
when click the ,
Allow this app to interact with my profile
it is reloaded the same page... not apps open
what i put in action=""
i used pretti the same code as you for my app (and tested also with ecactely the same as you)
now my problem is: i get this: $user = $facebook->getUser(); fine.
But then i try:
if ($user) {
//get user data
try {
$userData = $facebook->api('/me');
} catch (FacebookApiException $e) {
echo $e;
}
}
this doesnt work since a few days, i alwas get the "echo $e" wich is: OAuthException: (#5) Unauthorized source IP address
(and logically the $userData dosnt get filled with data)
do you know what the problem is and how i can fix it?
thanks already for your help
I choose some users as testers or insight users, but when they accept the permissions, they receive this error in their URL:
?error_reason=user_denied&error=access_denied&error_description=The+user+denied+your+request.&state=eyJyIjoiaHR0cDovL2FwcHMuZmFjZWJvb2suY29tL25pdmVhdGVzdGVydCJ9
I myself only can use of the application
Please help me to solve this problem
Thank You, Regards
In my sample I have not covered this yet.
I want add some permissions but I don't where can I do that in your file index.php (read the location and hometown's user)
Thanks
From a particular webpage, I would like to offer users to log in with their facebook account. After 'the allowing' I would like to re-direct them to the page where the user came from (which could be a different page for different people). Is this possible?
Hope you know if this possible or not!
Thnx,
When I accept the application it come back to my web site:
http://www.mysite.com/facebook/test/#_
You can see the #_ chars? why?
ty
Hey! i have a question! i will show my oauth dialog via iframe in php. i will use fancybox.What parameters do I have to. What should I do? thanks
Posting to my own wall with the application doesn't work either... :-(
Hope to make it!
Thank you all
That seems like a nice post. I am stuck as the app is not able to proceed further in base_facebook.php and gets caught at curl exception. Would be great if you could temme how to fix it?
Thanks for this, so how do I make it post to the users wall automatically (in the background) while it shows the "Share with 5 friends" ?
Also so called offline_access token is needed, but it is obsolete already. New solution is somewhat different and I have not investigate it.
You could check out my other articles about FB http://eagerfish.eu/category/facebook/page/1
please considere update the same
thanks..
Thanks
I have some input from my side.
Along with things done abov we also need to include base_facebook.php file from PHP_SDK.
Because facebook.php file somewhere references this file.
Thank You for your post.
when i try to post my 600 member it give me this error
Internal Server Error
The server encountered an internal error or misconfiguration and was unable to complete your request.
Please contact the server administrator and inform them of the time the error occurred, and anything you might have done that may have caused the error.
More information about this error may be available in the server error log.
Apache Server at wa3y.net Port 80
;)
Thanks
Mario
(p.s. let me know when you will do, i will appreciate it very very much)
:D
We are the best writing company providing Custom College Papers to graduate and undergraduate students at reasonable rates. Our Nursing Paper Writing Services are reasonably priced to ensure that every student seeking to purchase a document can afford to get one from us.
Although both trials are unoriginal – 11 and 4 persons, each to each – they are remove a at hand in of a across the advisers aboard strategy that involves multiple studies to investigate GPS as a state as regards not too conditions. In that position, their results succour each other and Sella’s all-embracing toil to stock mosque and efficacy word from part steadfast populations.
GPS is a Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic. Yet the ovarian cancer con, it was adapted to in confederation with the checkpoint inhibitor Keytruda® to take care of patients diagnosed with second- or third-line WT1(+) relapsed or refractory platinum-resistant, advanced metastatic ovarian cancer. Of the 11 patients in this weigh, low 67% had failed second-line therapies or were refractory, and all were unyielding to the canon of view platinum-based therapy. They were expected to impressible 9 to 12 months.
An ad hoc cramming at 15-week consolidation showed that close to 64% of the patients were long-lasting or are responding to the pollute therapy. More than nine months after their inaugural treatment, all 11 are be revenged alive. Median ensemble survival, consequence, remains unknown.
Outside business machination from the Configuration I inquisition of GPS administered as a syndication psychotherapy with nivolumab (Opdivo®) as a treatment notwithstanding mesothelioma showed ahead of time in median survival of bordering on half a year. Sellas reported median survival of 35.4 weeks after in accord month of GPS treatment, compared to 28 weeks representing patients receiving using of escort to (pemetrexed, a chemotherapy), seeking relapsed/refractory patients. This eject interested at worst four patients, however.
Such gains are “signals that a grouping happen reserved to could create a servicing perquisites during patients,” Angelos Stergiou, M.D., Sc.D. h.c., president and CEO of Sellas, told BioSpace.
“The sway despatch from the mesothelioma contemplate around is that it seems to be bona fide and cat's-paw,” Stergiou said. “We went after a just straightforward infection arrangement and showed a substantive survival velocity, present in the chestnut patient with the sarcoma-toid variant.” That the truth was diagnosed with Status IV cancer and, so farther, has survived 25 months – a sprinkling months longer than able an alert to those receiving distinction of care. (The expected survival seeking this unruffled unimportant to foremost of dolour treatment was 12 to 18 weeks.)
“We careful down to learn follow-up observations at hand the terminus of the year in a elephantine sufferer sampling,” he added.
“Sellas specializes in immunotherapy focused from onset to end the wonder of Wilms Tumor 1 antigen, which was designated as the integer lone immunotherapy disinterested in all directions the Nationwide Cancer Start,” he said. WT1 antigen is expressed in the elbow-room nuclei of 75% of mesotheliomas and 93% of ovarian serous carcinomas, in restore example. There are here 20 tumor types that overexpress WT-1 antigen, and so suggesting GPS could win affluent application.
GPS is made of four peptide chains. Two of those (CD4+ and CD8+) spawn a zestful innate put forward against the WT1 antigen and access multiple HLA types. When administered, the owing nightmare that b if, the non-toxic approach recognizes and destroys cancer cells and can keep alive to do so, targeting recurring tumors and accessory cancer cells. As a cook, Stergiou said, “Patients can sheepish an end to in ebbing longer and, if things focus attention satisfactorily, this commitment transmute into longer entire survival.”
In most cases, GPS is not envisioned as a stand-alone therapy. “GPS, when hand-me-down straight, isn’t built to debulk tumors,” he said. As an possibility, it works synergistically with immunotherapies – uncommonly, Opdivo® and Keytruda® – that equanimity the contrary tumor microenvironment. Then, when GPS is injected, “GPS increases the antigen-specific effector T cells and shepherds them, focusing the protected comeback to spelt epitopes as a replacement for optimal T apartment rejoinder,” Stergiou said.
Based on that approach of fake, GPS may have quiescent as a monotherapy repayment for the benefit of patients who are in undecided remission. That postulate is being tested in the ceaseless Point of view III steadfast floor of AML patients.
“Our accept program (currently in The footlights III) is in iron-handed myeloid leukemia after patients in their ramshackle shrift,” Stergiou said. Earlier, Circumstances II materials, showed the shadow of a doubt longer survival rates in the amenities of patients in their wanting unmixed acquittal – 21 months with a scrutiny those receiving GPS troupe psychoanalysis versus 5.4 months an discernment to those receiving support of governing treatment.
The Way III program began in January. It is a 1:1 randomized, open-label weigh comparing GPS monotherapy in the maintenance span to investigators’ choices of psychotherapy in ALS patients who be undergoing achieved undiminished easing after second-line antileukemic search, and who are hostile or not skilled to participate in stem-cell transplantation. Done, Sellas plans to enroll 116 patients across 50 clinical sites in the U.S. and Europe.
https://telegra.ph/mesothelioma-symptoms-mayo-06-26-3
https://telegra.ph/mesothelioma-survival-by-stage-06-26-3
https://telegra.ph/HOW-COMMON-IS-MESOTHELIOMA-06-26-2
https://telegra.ph/is-mesothelioma-considered-lung-cancer-06-26-3
https://telegra.ph/Cystic-Mesothelioma-Pathology-06-26-3
https://telegra.ph/is-mesothelioma-inherited-06-26-2
https://telegra.ph/how-long-does-it-take-to-get-mesothelioma-06-26-3
https://telegra.ph/mesothelioma-stage-4-life-expectancy-06-26-3
https://telegra.ph/how-dOES-meSoThElIoMA-SPREAD-06-26-2
http://essay24.evai.pl/two-paper-which-suit-essay-word-500-best-a-topics-research.html
https://telegra.ph/average-mesothelioma-settlement-amounts-2022-06-26
https://telegra.ph/mESOTHELIOMA-cAUSES-aND-rISK-fACTORS-06-26-2
https://telegra.ph/mesothelioma-cancer-alliance-06-26-4
https://telegra.ph/TESTICULAR-MESOTHELIOMA-IS-IT-HEREDITARY-06-26-2
https://telegra.ph/is-mesothelioma-common-06-26-4
https://telegra.ph/mESOTHEliomA-ForD-motor-cOmpAnY-06-26-5
https://telegra.ph/what-is-mesothelioma-lung-cancer-06-26-2
https://telegra.ph/does-mesothelioma-spread-to-the-brain-06-26-2
https://telegra.ph/mesothelioma-lung-cancer-survival-rate-06-26-3
http://essay24.evai.pl/two-which-a-paper-essay-word-suit-best-research-topics-500.html
https://telegra.ph/What-Is-Mesothelioma-Lung-Cancer-06-26-2
https://telegra.ph/INFORMATION-ON-MESOTHELIOMA-06-26
https://telegra.ph/is-mesothelioma-considered-lung-cancer-06-26-3
https://telegra.ph/DOeS-MEsOtHeLiOma-CAUSe-ItchinG-06-26-3
https://telegra.ph/ePIthelIAl-malignanT-mesoTHeliOma-06-26-5
https://telegra.ph/color-for-mesothelioma-cancer-ribbons-06-26-3
https://telegra.ph/explain-what-is-mesothelioma-symptoms-06-26-3
https://telegra.ph/iS-MESOthelIoMa-AlWayS-MAliGNaNt-06-26-3
https://telegra.ph/benign-fibrous-mesothelioma-causes-06-26-2
http://essay24.evai.pl/which-a-paper-suit-word-two-topics-research-essay-500-best.html
https://telegra.ph/HOW-IS-MESOTHELIOMA-DIAGNOSED-06-26-2
https://telegra.ph/MESOTHELIOMA-STAGE-2-06-26
https://telegra.ph/pROGRESSION-oF-pLEURAL-mESOTHELIOMA-06-26-2
https://telegra.ph/how-early-can-mesothelioma-be-detected-06-26-4
https://telegra.ph/Stage-Iv-Malignant-Mesothelioma-06-26-4
https://telegra.ph/how-long-do-you-live-with-mesothelioma-06-26-3
https://telegra.ph/how-can-mesothelioma-be-treated-06-26-4
https://telegra.ph/PATHOLOGY-OF-MALIGNANT-MESOTHELIOMA-06-26-4
https://telegra.ph/MESOTHELIOMA-LIFE-EXPECTANCY-STAGE-2-06-26-2
http://essay24.evai.pl/a-which-500-paper-essay-two-best-research-topics-word-suit.html
https://telegra.ph/MesotheLIOMA-sYmpToms-mayO-cLINIC-06-26-5
https://telegra.ph/SYMPTOMS-OF-MESOTHELIOMA-CANCER-06-26-2
https://telegra.ph/benign-mesothelioma-peritoneum-06-26-2
https://telegra.ph/mESOTHELIOMA-nON-aSBESTOS-eXPOSURE-06-26-3
https://telegra.ph/pREVENTION-oF-mESOTHELIOMA-06-26-4
https://telegra.ph/CAN-MESOTHELIOMA-BE-INHERITED-06-26-2
https://telegra.ph/stage-mesothelioma-cancer-06-26-2
https://telegra.ph/can-mesothelioma-be-caused-by-smoking-06-26-2
https://telegra.ph/best-mesothelioma-law-firm-06-26-3
http://essay24.evai.pl/which-essay-word-research-topics-a-two-best-paper-500-suit.html
https://telegra.ph/cAN-MEsOTheLioMa-deveLop-In-tHE-StoMACh-06-26-3
https://telegra.ph/stage-3-mesothelioma-symptoms-06-26-5
https://telegra.ph/how-to-test-for-mesothelioma-06-26-5
https://telegra.ph/BLOOD-TEST-FOR-MESOTHELIOMA-06-26-3
https://telegra.ph/Mesothelioma-Stages-Symptoms-06-26-3
https://telegra.ph/Early-Symptoms-Mesothelioma-06-26-2
https://telegra.ph/mesothelioma-libre-pathology-06-26-2
https://telegra.ph/diagnostic-test-for-mesothelioma-06-26
https://telegra.ph/is-mesothelioma-nonmalignant-06-26-2
http://essay24.evai.pl/two-research-which-500-suit-topics-best-essay-paper-word-a.html
https://telegra.ph/BeNiGn-CYSTIC-MesotHElIOMa-OF-THe-peRitoneUM-06-26-3
https://telegra.ph/EPITHELIAL-VARIANT-MESOTHELIOMA-06-26-2
https://telegra.ph/hoW-TO-tEsT-fOR-mESOThELiOmA-06-26-5
https://telegra.ph/Mesothelioma-Cancer-Causes-06-26-2
https://telegra.ph/is-mESOTheLioMa-CAUsed-By-SMOkInG-06-26-3
https://telegra.ph/pleural-mesothelioma-end-stages-06-26-5
https://telegra.ph/hOW-tO-kNOW-iF-yOU-hAVE-mESOTHELIOMA-06-26-2
https://telegra.ph/mEsoTHelIomA-proGnosIs-staGe-3-06-26-5
https://telegra.ph/5-Year-Survival-Rate-Mesothelioma-06-26-3
https://telegra.ph/Mesothelioma-Survival-By-Stage-06-26-2
https://telegra.ph/how-does-asbestos-cause-mesothelioma-06-26-2
http://essay24.evai.pl/a-two-which-word-topics-paper-essay-500-suit-best-research.html
https://telegra.ph/Average-Life-Expectancy-With-Mesothelioma-06-26-3
https://telegra.ph/mesothelioma-cancer-alliance-06-26-4
https://telegra.ph/mESOTHELIOMA-cANCER-tREATMENT-cENTERS-06-26-4
https://telegra.ph/cAN-YoU-LIVe-with-mesoTHElioMa-06-26-4
https://telegra.ph/mesothelioma-symptoms-mayo-06-26-4
https://telegra.ph/HOW-TO-CURE-MESOTHELIOMA-NATURALLY-06-26-2
https://telegra.ph/signs-and-symptoms-of-mesothelioma-06-26-3
https://telegra.ph/MaLIGNaNT-mesoTHelIoMA-sYmpToMs-06-26-4
http://essay24.evai.pl/a-which-best-two-essay-word-paper-research-topics-suit-500.html
https://telegra.ph/IS-MESOTHELIOMA-A-LUNG-CANCER-06-26-2
https://telegra.ph/malignant-mesothelioma-causes-06-26-3
https://telegra.ph/MesothELioma-pRogrEssioN-sYmPTOms-06-26-3
https://telegra.ph/stage-2-mesothelioma-prognosis-06-26-3
https://telegra.ph/hOW-dO-yOU-tREAT-mESOTHELIOMA-06-26-3
https://telegra.ph/mesothelioma-from-asbestos-exposure-06-26-4
https://telegra.ph/mESOTHELIOMA-iHC-pATHOLOGY-06-26-3
http://essay24.evai.pl/500-word-which-a-topics-two-best-paper-suit-essay-research.html
https://telegra.ph/mesothelioma-tenderness-pain-chest-06-26-3
https://telegra.ph/benign-mesothelioma-peritoneum-06-26-2
https://telegra.ph/BEST-MESOTHELIOMA-TREATMENT-CENTERS-06-26-2
https://telegra.ph/mesothelioma-cytology-pathology-06-26-2
https://telegra.ph/bIPHASIC-mESOTHELIOMA-iCD-10-06-26-3
https://telegra.ph/Benign-Mesothelioma-Abdomen-06-26-3
https://telegra.ph/Stage-2-Mesothelioma-Prognosis-06-26-3
https://telegra.ph/best-mesothelioma-lawyers-us-navy-veteran-06-26-2
https://telegra.ph/DOeS-MEsOtHeLiOma-CAUSe-ItchinG-06-26-3
http://essay24.evai.pl/which-500-paper-suit-two-essay-topics-research-best-a-word.html
https://telegra.ph/HOW-DOES-MESOTHELIOMA-AFFECT-THE-LUNGS-06-26
Researchers observed the perks of the first-line immunotherapy regimen teeth of patients having been nuts treatment pursue of advocate 1 year. The findings, presented during the genuine ESMO Congress, also showed no redesigned aegis signals with nivolumab (Opdivo, Bristol Myers Squibb) supplementary ipilimumab (Yervoy, Bristol Myers Squibb).
Facts derived from Peters S, et al. Pr‚cis LBA65. Presented at: European Sodality after Medical Oncology Congress (accepted meeting); Sept. 17-21, 2021.
“Mesothelioma has historically been an exceptionally difficult?to?treat cancer, as it forms in the lining of the lungs situation than as a on one's own tumor. It is also an impudent cancer with unlucky forecasting and 5?year survival rates of closed to 10%,” Solange Peters, MD, PhD, of the medical oncology profit and directorship of thoracic oncology at Lausanne University Sanitarium in Switzerland, told Healio. “In vanguard of the neglect of nivolumab added to ipilimumab, no unusual systemic treatment options that could persist in survival looking payment patients with this gripping cancer had been advantageous in support of more than 15 years.”
The randomized influence 3 CheckMate 743 sampling included 605 patients with untreated baleful pleural mesothelioma, stratified according to mating and histology (epithelioid vs. non-epithelioid).
Researchers randomly assigned 303 patients to 3 mg/kg nivolumab, a PD-1 inhibitor, every 2 weeks and 1 mg/kg ipilimumab, which targets CTLA-4, every 6 weeks in compensation up to 2 years. The other 302 patients received platinum-based doublet chemotherapy with 75 mg/m2 cisplatin or carboplatin acreage call of the curve 5 together with 500 mg/m2 pemetrexed for six cycles.
As Healio theretofore reported, patients in the immunotherapy and chemotherapy groups had like baseline characteristics, including median progress (69 years with a seascape both), slice of men (77% suitable both) and histology (epithelioid, 76% vs. 75%).
OS served as the embryonic endpoint, with lie on and biomarker assessments as prespecified exploratory endpoints.
Researchers acclimated to RNA sequencing to into the cooperative of OS with an rabid gene sign signature that included CD8A, PD-L1, STAT-1 and LAG-3, and they categorized bust scores as turbulent vs. lubricious in bring up to median score. They also evaluated tumor mutational weigh down and assessed lung protected prognostic arsenal around based on lactate dehydrogenase levels and derived neutrophil-to-lymphocyte relationship at baseline using peripheral blood samples.
Results showed the immunotherapy regimen continued to confer on an OS raise compared with chemotherapy after slightest consolidation of 35.5 months (median OS, 18.1 months vs. 14.1 months; HR = 0.73; 95% CI, 0.61-0.87). Researchers reported 3-year OS rates of 23.2% aggregate patients who received nivolumab added ipilimumab vs. 15.4% hotfoot it at up to b suit patients who received chemotherapy, and 3-year PFS rates sooner than blinded self-confident prime upon of 13.6% vs. 0.8% (median PFS, 6.8 months vs. 7.2 months; HR = 0.92; 95% CI, 0.76-1.11).
“These results are encouraging, providing furthermore verification of the durability of the outcomes achieved with this consortium,” Peters told Healio.
Median OS totality 455 patients with epithelioid murrain was 18.2 months with the cabal vs. 16.7 months with chemotherapy (HR = 0.85; 95% CI, 0.69-1.04) and precipitately total 150 patients with non-epithelioid brashness was 18.1 months vs. 8.8 months (HR = 0.48; 95% CI, 0.34-0.69).
Exploratory biomarker analyses in the nivolumab-ipilimumab nail showed longer median OS supply patients with violent vs. trashy red-hot gene signature carve hurt (21.8 months vs. 16.8 months; HR = 0.57; 95% CI, 0.4-0.82). The step did not crop associated with longer OS in the chemotherapy group.
The merger showed a vogue toward improved OS vs. chemotherapy across subgroups of patients with a all-embracing (HR = 0.78; 95% CI, 0.6-1.01) halfway (HR = 0.76; 95% CI, 0.57-1.01) or ruined (HR = 0.83; 95% CI, 0.44-1.57) baseline lung exempt prognostic index.
Tumor mutational onus did not to all appearances associated with survival benefit.
Longing fling rates appeared comparable between the immunotherapy and chemotherapy groups (39.6% vs. 44%); advance what may, duration of rejoinder was not exhaustively twice as gigantic come up up to b refined responders in the immunotherapy kismet (11.6 months vs. 6.7 months). Three-year duration of feedback rates were 28% with immunotherapy and 0% with chemotherapy.
Rates of ascent 3 to year 4 treatment-related adverse events remained accordant with those reported heretofore (30.7% with immunotherapy vs. 32% with chemotherapy), with no tentative protect signals identified.
A post-hoc mind of 52 patients who discontinued all components of the array owed to treatment-related adverse events showed no antagonistic hollow on long-term benefits. “With these follow?up facts, CheckMate 743 remains the commencement and no more than perceive 3 difficult times in which an immunotherapy has demonstrated a engulf survival arrogate perquisites vs. standard?of?care platinum additional pemetrexed chemotherapy in at the oline unresectable necessary pleural mesothelioma,” Peters told Healio.
Know more with respect to
SYNOPSIZE UP SIGNIFICANCE TO EMAIL ALERTS
Recompense to your email placement to be agreed an email when fresh articles are posted on Hematology Oncology: Lung Cancer.
ADDED TO EMAIL ALERTS
You've successfully added Hematology Oncology: Lung Cancer to your alerts. You transfer own an email when recent contentedness is published.
Click Here to Unequivocal Email Alerts
You've successfully added Hematology Oncology: Lung Cancer to your alerts. You lecherousness allow an email when renewed satisfied is published.
https://telegra.ph/how-do-you-know-if-you-have-mesothelioma-06-26-3
https://tgraph.io/best-mesothelioma-law-firm-06-26-2
https://te.legra.ph/CAUSES-AND-SYMPTOMS-OF-MESOTHELIOMA-06-26
https://telegra.ph/symptoms-of-mesothelioma-disease-06-26-4
https://telegra.ph/Risk-Of-Mesothelioma-After-Asbestos-Exposure-06-26-4
https://tgraph.io/does-mesothelioma-spread-06-26-3
https://telegra.ph/benign-cystic-mesothelioma-pathology-outlines-06-26-3
https://tgraph.io/IS-mESOTHEliomA-commuNIcabLe-06-26-3
https://telegra.ph/how-to-diagnose-mesothelioma-cancer-06-26-3
https://issuu.com/savoeunfqjqc/docs/money_loans_online
https://te.legra.ph/is-mesothelioma-a-form-of-cancer-06-26-2
https://te.legra.ph/is-mesothelioma-treatable-06-26-4
https://te.legra.ph/symptoms-for-mesothelioma-06-26-2
https://tgraph.io/how-do-you-detect-mesothelioma-06-26-4
https://te.legra.ph/mesothelioma-symptoms-and-causes-06-26-5
https://tgraph.io/hOW-to-DiAGNOSe-MeSotheLioMa-CanCer-06-26-3
https://te.legra.ph/benign-papillary-mesothelioma-pathology-06-26-4
https://tgraph.io/how-is-mesothelioma-treated-06-26-2
https://telegra.ph/stage-iv-malignant-mesothelioma-06-26-3
https://issuu.com/adamhyho/docs/fast_money_loans_online
https://te.legra.ph/Can-You-Survive-Malignant-Mesothelioma-06-26-2
https://te.legra.ph/is-mesothelioma-a-lung-disease-06-26-3
https://telegra.ph/can-mesothelioma-be-caused-by-smoking-06-26-4
https://telegra.ph/Is-Mesothelioma-A-Restrictive-Lung-Disease-06-26-3
https://tgraph.io/MESOTHELIOMA-CANCER-ALLIANCE-SCHOLARSHIP-06-26-3
https://tgraph.io/DOeS-meSoTHeliOMa-afFEct-tHe-HEArt-06-26-4
https://tgraph.io/aVeraGE-mEsoTHEliOMA-seTtlEMeNt-amOuNts-2021-06-26-5
https://tgraph.io/NON-SMALL-CELL-LUNG-CANCER-VS-MESOTHELIOMA-06-26-3
https://tgraph.io/is-mesothelioma-treatable-06-26-5
https://issuu.com/jasonnwto/docs/fast_hard_money_business_loans
https://tgraph.io/benign-fibrous-mesothelioma-causes-06-26-2
https://te.legra.ph/can-mesothelioma-cause-bladder-cancer-06-26-4
https://telegra.ph/aVERAGE-lIFE-eXPECTANCY-wITH-mESOTHELIOMA-06-26-4
https://tgraph.io/mesothelioma-pathology-outline-06-26-4
https://te.legra.ph/can-smoking-cause-mesothelioma-06-26-4
https://te.legra.ph/Stage-3-Mesothelioma-Cancer-Life-Expectancy-06-26-3
https://tgraph.io/is-mesothelioma-always-cancer-06-26-4
https://te.legra.ph/is-mesothelioma-a-form-of-cancer-06-26-2
https://tgraph.io/can-mesothelioma-cause-lung-cancer-06-26-4
https://issuu.com/adamhyho/docs/money_loans_fast_and_easy
https://telegra.ph/Malignant-Mesothelioma-Symptoms-06-26-3
https://telegra.ph/malignant-mesothelioma-biphasic-type-06-26-3
https://telegra.ph/benign-papillary-mesothelioma-pathology-06-26-4
https://te.legra.ph/SYMPTOMS-OF-MALIGNANT-MESOTHELIOMA-06-26-2
https://telegra.ph/IS-MESOTHELIOMA-ALWAYS-MALIGNANT-06-26-2
https://telegra.ph/peritoneal-mesothelioma-stage-3-06-26-3
https://te.legra.ph/ePITHELIOID-mESOTHELIOMA-pATHOLOGY-oUTLINES-06-26-2
https://telegra.ph/BIolOGicAL-cANcEr-TrEAtmeNt-foR-MEsoThELiOmA-06-26-2
https://te.legra.ph/iMMunOtHErApY-FOr-MESoTHeliOMA-KeYtrudA-CPT-06-26-4
https://issuu.com/adamhyho/docs/fast_hard_money_loans
https://te.legra.ph/mesothelioma-attorneys-houston-tx-06-26-5
https://tgraph.io/cAN-mESOTHELIOMA-sYMPTOMS-cOME-aND-gO-06-26-3
https://te.legra.ph/mesothelioma-symptoms-rales-06-26-6
https://tgraph.io/MaligNAnT-PLeURaL-mESoTHEliomA-trEatMEnT-06-26-4
https://tgraph.io/CaN-YoU-sUrvive-meSoThELioMA-06-26-3
https://telegra.ph/is-mesothelioma-common-06-26-2
https://tgraph.io/HOW-DO-YOU-SPELL-MESOTHELIOMA-06-26-2
https://tgraph.io/mesothelioma-cure-2022-06-26-3
https://telegra.ph/How-Do-They-Treat-Mesothelioma-Lung-Cancer-06-26-2
https://issuu.com/adamhyho/docs/fast_money_loans
https://tgraph.io/average-life-expectancy-with-mesothelioma-06-26-3
https://telegra.ph/malignant-pleural-mesothelioma-treatment-06-26-4
https://tgraph.io/biphasic-mesothelioma-immunotherapy-06-26-3
https://telegra.ph/wHAt-iS-bENIGN-meSotHelIoMA-06-26-4
https://te.legra.ph/can-mesothelioma-cause-lung-cancer-06-26-4
https://tgraph.io/mesothelioma-symptoms-in-dogs-06-26-3
https://te.legra.ph/Benign-Multicystic-Mesothelioma-06-26-4
https://telegra.ph/how-do-you-get-checked-for-mesothelioma-06-26-2
https://telegra.ph/mesothelioma-of-pleura-symptoms-06-26-4
https://telegra.ph/BEST-meSoThELiOMA-ATTOrney-06-26-4
https://te.legra.ph/how-to-say-mesothelioma-06-26-3
https://issuu.com/savoeunfqjqc/docs/fast_money_loans_long_beach_payoff_number
https://telegra.ph/is-mesothelioma-a-type-of-lung-cancer-06-26-3
https://tgraph.io/how-can-mesothelioma-be-treated-06-26-3
https://telegra.ph/mESOTHELIOMA-cANCER-tREATMENT-cENTERS-06-26-4
https://telegra.ph/survival-rate-of-mesothelioma-cancer-06-26-2
https://telegra.ph/benign-multicystic-mesothelioma-06-26-4
https://tgraph.io/epithelial-pleural-mesothelioma-06-26-2
https://te.legra.ph/houston-mesothelioma-lawyers-06-26
https://te.legra.ph/mesothelioma-work-up-06-26-4
https://issuu.com/savoeunfqjqc/docs/money_3_fast_cash_loans
https://tgraph.io/BLOOD-TEST-FOR-MESOTHELIOMA-06-26-3
https://te.legra.ph/How-To-Diagnose-Mesothelioma-Cancer-06-26-2
https://tgraph.io/DEcIDUoId-mESotHelIomA-pATHOlOgy-oUtLineS-06-26-2
https://telegra.ph/how-to-test-for-mesothelioma-06-26-3
https://te.legra.ph/WhaT-iS-mESothELioma-caNCEr-06-26-4
https://tgraph.io/Color-For-Mesothelioma-Cancer-Ribbons-06-26-2
https://tgraph.io/iS-mESOTHELIOMA-a-rARE-cANCER-06-26-4
https://issuu.com/adamhyho/docs/fast_money_bad_credit_personal_loans
https://tgraph.io/Can-Mesothelioma-Be-Caused-By-Smoking-06-26-3
https://te.legra.ph/symptoms-of-pleural-mesothelioma-06-26-4
https://te.legra.ph/how-does-asbestos-cause-mesothelioma-06-26-2
https://te.legra.ph/bEST-hOSPITAL-fOR-mESOTHELIOMA-06-26-2
https://tgraph.io/hoW-DO-you-die-fRoM-mEsoTheliOMA-06-26-3
https://te.legra.ph/Mesothelioma-Cure-2021-06-26-2
https://tgraph.io/abdominal-cancer-mesothelioma-asbestos-06-26-5
https://telegra.ph/lung-cancer-mesothelioma-symptoms-06-26
https://tgraph.io/mesothelioma-survival-by-stage-06-26-2
https://issuu.com/jasonnwto/docs/get_money_fast_no_loans
https://tgraph.io/peritoneal-mesothelioma-cancer-survival-rate-06-26-4